Compare WHWK & IGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WHWK | IGI |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | 22 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 179.8M | 97.0M |
| IPO Year | N/A | 2009 |
| Metric | WHWK | IGI |
|---|---|---|
| Price | $3.92 | $16.29 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 170.8K | 10.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.39 | $15.78 |
| 52 Week High | $4.40 | $17.09 |
| Indicator | WHWK | IGI |
|---|---|---|
| Relative Strength Index (RSI) | 62.91 | 58.85 |
| Support Level | $1.84 | $16.33 |
| Resistance Level | $4.40 | $16.60 |
| Average True Range (ATR) | 0.25 | 0.18 |
| MACD | 0.01 | 0.04 |
| Stochastic Oscillator | 99.36 | 81.82 |
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.
Western Asset Invstm Grd Dfnd Opp Tr Inc operates as a non-diversified closed-end management investment company. Its primary investment objective is to provide current income and then liquidate & distribute substantially all of the Fund's net assets to stockholders. As a secondary investment objective, the Fund will seek capital appreciation. The Fund seeks to achieve its investment objectives by investing at least 80% of its net assets in investment-grade corporate fixed-income securities of varying maturities.